glp-1 receptor agonists and cardiovascular outcome trials an update Mechanisms of action of glucagon-like peptide 1 in diseases Cardiovascular in individuals with type 2 diabetes mellitus demonstrate that glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce Roche obesity drug shows Size:40 Servings copy

glp-1 receptor agonists and cardiovascular outcome trials an update Mechanisms of action of glucagon-like peptide 1 in diseases Cardiovascular in individuals with type 2 diabetes mellitus demonstrate that glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce Roche obesity drug shows Size:40 Servings copy

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo | Reuters

Weight loss was stedy for 14 months before plateauing

copy

Size:40 Servings

Sugars have been associated with various signalling pathways, which initiate depolarisation of the L-cell membrane causing an elevated concentration of cytosolic Ca 2+ , which in turn induces GLP-1 secretion